Recurrent or Metastatic Head and Neck Carcinoma Clinical Trial
Official title:
Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy
Verified date | February 2019 |
Source | Pierre Fabre Medicament |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
For patients relapsing after platinum-based therapy, few data are available. The current use
of cetuximab associated with radiotherapy in localized disease and associated with
platinum-based chemotherapy in the first-line setting stresses the need for new therapeutic
options at later stages of SCCHN.Vinca-alkaloids demonstrated activity in SCCHN. Vinflunine
demonstrated superior antitumour activity to vinorelbine in preclinical animal models. Recent
preliminary phase I results of the vinflunine plus methotrexate combination in SCCHN, based
on a clinical review, show encouraging antitumour activity and an acceptable safety profile.
Therefore the combination of vinflunine and methotrexate appears a promising salvage regimen
after platinum failure.
The present study has been designed as a multicenter, randomised phase III study which will
compare the combination of IV vinflunine with methotrexate to methotrexate alone in SCCHN
patients having failed platinum-based therapy.
Status | Completed |
Enrollment | 459 |
Est. completion date | November 23, 2018 |
Est. primary completion date | October 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed recurrent and/or metastatic squamous cell carcinoma - Documented progressive disease after chemotherapy for locoregionally advanced or recurrent/metastatic SCCHN which included a platinum derivative - Measurable or non measurable disease - adequate haematological, hepatic and renal functions - WHO performance status < 1 Exclusion Criteria: - Nasopharyngeal carcinoma - History of brain or leptomeningeal involvement - Albumin level < 35 g/L - Patients with weight loss = 5% within the last 3 months - Grade > 2 peripheral neuropathy at study entry - "Third space" fluids (pleural effusion, ascites, massive edema) - Prior treatment with vinca-alkaloids and methotrexate |
Country | Name | City | State |
---|---|---|---|
France | Institut de Recherche Pierre Fabre | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Pierre Fabre Medicament |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival in the ITT Population (Months) | Time from randomization to the date of death or last follow-up. The survival duration of patients still alive, was censored at the date of last contact or last follow-up. | Participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months | |
Secondary | Progression Free Survival | Time measured from the date of randomisation until date of progression or death from any cause (whichever came first) | an expected average of 4 months | |
Secondary | Objective Response Rate (ORR) | The objective response is defined as the best response designation recorded across all time points from the date of randomisation until disease progression. | 6 weeks | |
Secondary | Disease Control Rate | Percentage of best overall responses CR, PR and SD in the analysed population | 30 months | |
Secondary | Duration of Response | Duration of objective response will be measured for responders (CR+PR) from the time for CR or PR until the 1st date of documentation of recurrent or progressive disease or the date of death any cause. | 30 months |